- Micron’s stock rises as enthusiasm builds ahead of earnings
- This biotech is working on a GLP-1 pill that could be better than the Wegovy version
- Nebius’ stock falls as investors get a wakeup call on the cost of competing in AI
- The IRS has changed the tax rules for 2026 — here’s how to keep more money and not overpay
- 3 signals that reveal if the Iran oil shock is just a blip — or the new normal
- Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales
